{"summary": "Author describes buying BFRI ahead of FDA approval, which was granted for Ameluz in superficial basal cell carcinoma, yet the stock fell 11% and kept dropping.", "reason": "event_recap_no_directional_thesis", "ideas": [], "model": "deepseek-flash", "failure_count": 0}